Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

(2021) David S. Ettinger et al.   Journal of the National Comprehensive Cancer Network

Phenotypic and Proteomic Analysis Identifies Hallmarks of Blood Circulating Extracellular Vesicles in NSCLC Responders to Immune Checkpoint Inhibitors

(2021) Davide Brocco et al.   Cancers

Circadian clock: a regulator of the immunity in cancer

(2021) Zhen Zhang et al.   Cell Communication and Signaling

The role of the circadian clock in cancer hallmark acquisition and immune-based cancer therapeutics

(2021) Elizabeth Cash et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Circadian regulation of cancer cell and tumor microenvironment crosstalk

(2021) Wenjing Xuan et al.   TRENDS IN CELL BIOLOGY

Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases

(2021) Christian Bailly et al.   Cancers

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

(2021) David C Qian et al.   LANCET ONCOLOGY

Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer.

(2020) Abdoulaye Karaboué et al.   JOURNAL OF CLINICAL ONCOLOGY

Downregulation of the circadian rhythm regulator HLF promotes multiple-organ distant metastases in non-small cell lung cancer through PPAR/NF-κb signaling

(2020) Jiarong Chen et al.   CANCER LETTERS

Circadian rhythm influences induction of trained immunity by BCG vaccination

(2020) L. Charlotte J. de Bree et al.   JOURNAL OF CLINICAL INVESTIGATION

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker

(2020) Zhengyi Wang et al.   Cancer Medicine

Research on circadian clock genes in non-small-cell lung carcinoma

(2019) Mengjun Qiu et al.   CHRONOBIOLOGY INTERNATIONAL

Association of Checkpoint Inhibitor–Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non–Small Cell Lung Cancer

(2019) Fiamma Berner et al.   JAMA Oncology

The circadian clock of CD8 T cells modulates their early response to vaccination and the rhythmicity of related signaling pathways

(2019) Chloé C. Nobis et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

(2019) Scott J Antonia et al.   LANCET ONCOLOGY

Circadian rhythms in adaptive immunity

(2019) Polly Downton et al.   IMMUNOLOGY

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

(2018) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

OUP accepted manuscript

(2018)   ANNALS OF ONCOLOGY

Lymphocyte Circadian Clocks Control Lymph Node Trafficking and Adaptive Immune Responses

(2017) David Druzd et al.   IMMUNITY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Systems Chronotherapeutics

(2017) Annabelle Ballesta et al.   PHARMACOLOGICAL REVIEWS

Nivolumab and Pembrolizumab for Non-Small Cell Lung Cancer

(2016) D. Morgensztern et al.   CLINICAL CANCER RESEARCH

The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis

(2016) Pedro N Aguiar et al.   Immunotherapy

A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker

(2016) Pedro N Aguiar et al.   Immunotherapy

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dosing-Time Makes the Poison: Circadian Regulation and Pharmacotherapy

(2016) Robert Dallmann et al.   TRENDS IN MOLECULAR MEDICINE

Morning vaccination enhances antibody response over afternoon vaccination: A cluster-randomised trial

(2016) Joanna E. Long et al.   VACCINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

(2015) Luisa Carbognin et al.   PLoS One

Circadian Clock Proteins and Immunity

(2014) Anne M. Curtis et al.   IMMUNITY

Comparison of circadian characteristics for cytotoxic lymphocyte subsets in non-small cell lung cancer patients versus controls

(2011) Gianluigi Mazzoccoli et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Circadian Variation of the Response of T Cells to Antigen

(2011) E. E. Fortier et al.   JOURNAL OF IMMUNOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

(2009) M. Ahmadzadeh et al.   BLOOD